CLINICAL AND LABORATORY STANDARDS INSTITUTE®

1st Edition

AUTO16

Next-Generation *In Vitro* Diagnostic Instrument Interface

This standard applies to the exchange of analytical testing data between *in vitro* diagnostic instruments and health care informatics systems.

A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes,* is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org

AUTO16, 1st ed.
April 2019

Next-Generation *In Vitro* Diagnostic Instrument Interface

Ed Heierman, PhD
Andrzej J. Knafel, PhD, CISA, CISSP, CCSP
Peter Barnecut
Nancy Dubrowny, MS, MT(ASCP)SC
Luis A. Eguren
Lenny Johnson
Laurent Lardin, MS
Dan Nguyen
Jordan Olson, MD
Haridas Puthiyapurayil
Dmytro Rud
Shilpa Taneja
William B. Williams
James Wulkan
John Yundt-Pacheco

Abstract

Clinical and Laboratory Standards Institute standard AUTO16—*Next-Generation* In Vitro *Diagnostic Instrument Interface* defines a connectivity standard based on the Laboratory Analytical Workflow (LAW) Profile[1] of the Integrating the Healthcare Enterprise organization, which originated from the work of the IVD Industry Connectivity Consortium. In addition to the LAW Profile, this standard includes implementation and integration guidance, security considerations, examples, and other supplemental information. The intended users of this standard are *in vitro* diagnostic system manufacturers, as well as the personnel and information technology management of medical laboratories.

Clinical and Laboratory Standards Institute (CLSI). *Next-Generation* In Vitro *Diagnostic Instrument Interface.* 1st ed. CLSI standard AUTO16 (ISBN 978-1-68440-041-6 [Print]; ISBN 978-1-68440-042-3 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2019.

Suggested Citation

CLSI. *Next-Generation* In Vitro *Diagnostic Instrument Interface.* 1st ed. CLSI standard AUTO16. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.

ISBN 978-1-68440-041-6 (Print)
ISBN 978-1-68440-042-3 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic) Volume 39, Number 4

Committee Membership

Consensus Council

Dennis J. Ernst, MT(ASCP), NCPT(NCCT)
Chairholder
Center for Phlebotomy Education
USA

Mary Lou Gantzer, PhD, FACB
Vice-Chairholder
USA

Julia H. Appleton, MT(ASCP), MBA
Centers for Medicare & Medicaid Services
USA

J. Rex Astles, PhD, FACB, DABCC
Centers for Disease Control and Prevention
USA

Thomas R. Fritsche, MD, PhD, FCAP, FIDSA
Marshfield Clinic
USA

Loralie J. Langman, PhD, DABCC, FACB, F-ABFT
Mayo Clinic
USA

Tania Motschman, MS, MT(ASCP)SBB
Laboratory Corporation of America
USA

James R. Petisce, PhD
BD Diagnostic Systems
USA

Andrew Quintenz
Bio-Rad Laboratories, Inc.
USA

Robert Rej, PhD
New York State Department of Health – Wadsworth Center
USA

Zivana Tezak, PhD
FDA Center for Devices and Radiological Health
USA

Document Development Committee on Next Generation IVD Instrument Interface

Ed Heierman, PhD
Chairholder
Abbott
USA

Andrzej J. Knafel, PhD, CISA, CISSP, CCSP
Vice-Chairholder
Roche Diagnostics International, Ltd.
Switzerland

Luis A. Eguren
North Shore LIJ Laboratories
USA

Daniele Fava
Inpeco SA
Switzerland

Lenny Johnson
Diagnostica Stago
USA

Laurent Lardi..., MS
bioMérieux, Inc.
France

Jordan Olson, MD
Geisinger Medical Center
USA

Shilpa Taneja
Beckman Coulter
USA

Staff

Clinical and Laboratory Standards Institute
USA

David E. Sterry, MT(ASCP)
Project Manager

Megan L. Tertel, MA, ELS
Editorial Manager

Catherine E.M. Jenkins
Editor

Kristy L. Leirer, MS
Editor

Laura Martin
Editor

Acknowledgment for the Expert Panel on Automation and Informatics

CLSI, the Consensus Council, and the Document Development Committee on Next Generation IVD Instrument Interface gratefully acknowledge the Expert Panel on Automation and Informatics for serving as technical advisors and subject matter experts during the development of this standard.

Expert Panel on Automation and Informatics

Ed Heierman, PhD
Chairholder
Abbott
USA

Jyh-Ching Yaur
Vice-Chairholder
Siemens Healthcare Diagnostics Inc.
USA

Ulysses J. Balis, MD
University of Michigan
USA

Ettore Cavallaro, PhD
Ortho Clinical Diagnostics
France

David Chou, MD
University of Washington Medical Center
USA

Nancy Dubrowny, MS, MT(ASCP)SC
BD Preanalytical Systems
USA

Andrzej J. Knafel, PhD, CISA, CISSP, CCSP
Roche Diagnostics International, Ltd.
Switzerland

Elizabeth Kenimer Leibach, EdD, MS, MLS(ASCP)^{CM}, SBB^{CM}
Rutgers University
USA

Manjula G. Ralalage, MBBS, MSc
Centers for Disease Control and Prevention
USA

Richard S. Seaberg, MT(ASCP)
Northwell Health
USA

Li You, PhD
FDA Center for Devices and Radiological Health
USA

Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Next Generation IVD Instrument Interface gratefully acknowledge the following volunteers for their important contributions to the development of this standard:

Peter Barnecut
Beckman Coulter
USA

Nancy Dubrowny, MS, MT(ASCP)SC
BD Preanalytical Systems
USA

Dan Nguyen
Abbott Laboratories
USA

Haridas Puthiyapurayil
Abbott Diagnostics
USA

Dmytro Ru
Roche Diagnostics International Ltd
Switzerland

William B. Williams
Abbott Diagnostics
USA

James Wulkan
Beckman Coulter
USA

John Yundt-Pacheco
Bio-Rad Laboratories
USA

Contents

Foreword

This standard is a successor to CLSI documents LIS01[2] and LIS02[3] (see Appendix A for a description of differences) for the next generation of *in vitro* diagnostic (IVD) instruments and discusses the connectivity challenges present in medical laboratories. This standard leverages the work of the IVD Industry Connectivity Consortium and Integrating the Healthcare Enterprise (IHE) organizations through the use of the Laboratory Analytical Workflow (LAW) Profile. Benefits of this new IVD system connectivity protocol include:

- Improved interoperability through the use of modern health care connectivity protocols and network technologies
- A more consistent interface across instruments with differing capabilities
- Substantial reduction in connectivity installation cost and time
- Improved integrity of patient result data
- Standardized data flow of IVD patient and quality control test work order steps and results between instrument, middleware, and laboratory information systems or laboratory automation systems
- Support for common testing workflows, such as rerun and reflex testing
- The availability of extensive resources for use during implementation and testing

In addition, this standard supplements the LAW Profile by:

- Providing guidance to vendors on implementing the LAW Profile
- Providing guidance to health care providers on integrating IVD systems implementing the LAW Profile
- Consolidating the LAW elements of the IHE Laboratory Technical Framework to improve profile usability
- Offering guidance on securing the interface

NOTE: The content of this standard is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

Key Words

Analyzer, HL7, IHE, interoperability, interface, IVD instrument, LAW Profile, security

Use of HL7®, LOINC®, CDA®, and SNOMED CT® in this standard are not endorsements on the part of CLSI.

Next-Generation *In Vitro* Diagnostic Instrument Interface

Chapter 1: Introduction

This chapter includes:

- Standard's scope and applicable exclusions
- Background information pertinent to the standard's content
- "Note on Terminology" that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the standard
- Abbreviations and acronyms used in the standard

1.1 Scope

This standard specifies requirements for the data exchange associated with the analytical workflow between medical laboratory *in vitro* diagnostic (IVD) instruments and the systems managing their work. This data exchange includes test orders and test results for both patients and QC specimens. Additional guidance is also provided to aid in the standard's adoption and implementation. This standard applies to all medical laboratory specialties (including blood bank testing). The intended users of this standard are IVD instrument vendors, IVD software systems vendors (LIS and middleware), and medical laboratory information technology (IT) personnel. This standard:

- Does not apply to point-of-care information exchange, which is already standardized by CLSI document POCT01[4]
- Does not apply to imaging information exchange, which is already standardized by digital imaging and communications in medicine (DICOM)
- Is not intended to standardize the features of IVD instruments or IVD software systems, only their external connectivity
- Does not apply to communication between systems already covered by other Integrating the Healthcare Enterprise (IHE) profiles (ie, laboratory testing workflow [LTW] and laboratory device automation [LDA])
- Does not cover calibration data, configuration information, standardization of test or analyte nomenclature (eg, LOINC®[a] [Logical Observation Identifiers Names and Codes]), or process status monitoring
- Does not discuss data privacy requirements

[a] LOINC® is a registered US trademark of Regenstrief Institute, Inc.